Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP-mediated pharmacologic interference with optimal platelet inhibition.

Journal of cardiovascular translational research - 1 Jun 2013

Cuisset Thomas, Quilici Jacques

Abstract excerpt

Variability of response to clopidogrel and prasugrel is a multifactorial process, with clinical consequences, and drug-drug interactions have been proposed as potential factors. Biological modulation of clopidogrel response has been demonstrated for atorvastatin and omeprazole. However, investiga...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Blood Platelets
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pharmacogenetics

Share to Platelet Aggregation Inhibitors

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 23314910
DOI: 10.1007/s12265-012-9442-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23314910-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP-mediated pharmacologic interference with optimal platelet inhibition.PMID 23314910Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.Semantic proximity Read ↗

Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.Semantic proximity Read ↗

Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia.Semantic proximity Read ↗

Mechanisms of variability in antiplatelet agents response.Semantic proximity Read ↗

Response variability to P2Y12 receptor inhibitors: expectations and reality.Semantic proximity Read ↗

A Phase 1 Study of Novel Antiplatelet Agent to Overcome Pharmacogenomic Limitations of ClopidogrelSemantic proximity Read ↗

Antiplatelet therapy: controversial aspects.Semantic proximity Read ↗

Options to overcome clopidogrel response variability.Semantic proximity Read ↗

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.Semantic proximity Read ↗

Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.Semantic proximity Read ↗

P-glycoprotein: a focus on characterizing variability in cardiovascular pharmacotherapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.